The FDA approved a knee pain treatment, Zilretta, developed by Flexion Therapeutics, paving the way for the 10-year-old Burlington company to add around 100 sales jobs and begin generating sales revenue.
Flexion Therapeutics will annouce the price in the newxt few days , however is expected to cost about $500 for each dose. Patients would receive injections in their knees at the office of an orthopedic specialist, a procedure that would take less than a minute.
Industry experts have predicted that the drug could eventually generate $600 million to $1.4 billion annually.
Since going public in 2014, Flexion has grown from roughly a dozen employees to around 140. The company now plans to add around 100 field representatives to sell Zilretta, which is expected to be available in the U.S. by the end of October.
“We see Zilretta as the first step in what will be a long and fruitful journey,” Flexion CEO Mike Clayman said in an interview. “We are ready to rock and roll.”
Source: The Boston Globe